These data collectively showed that HMCLs displayed mutations/deletions related to myeloma cells from patients at diagnosis (KRAS, DIS3, EGR1, PRDM1 and BIRC3) and relapse/progression to PCL (TP53, NRAS, BRAF, FANC genes). This evidence concerns the gene BRAF and plasma cell leukemia.